Publicacións nas que colabora con Sergio Raposeiras Roubín (83)

2022

  1. Differences Between Takotsubo and the Working Diagnosis of Myocardial Infarction With Nonobstructive Coronary Arteries

    Frontiers in Cardiovascular Medicine, Vol. 9

2021

  1. Evaluation of optimal medical therapy in acute myocardial infarction patients with prior stroke

    Therapeutic Advances in Chronic Disease, Vol. 12

2020

  1. Incidence, predictors and prognostic impact of intracranial bleeding within the first year after an acute coronary syndrome in patients treated with percutaneous coronary intervention

    European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 7, pp. 764-770

  2. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects

    European heart journal. Cardiovascular pharmacotherapy, Vol. 6, Núm. 1, pp. 31-42

  3. The impact of optimal medical therapy on patients with recurrent acute myocardial infarction: Subanalysis from the BleeMACS study

    International Journal of Cardiology, Vol. 318, pp. 1-6

2018

  1. Association of Beta-Blockers with Survival on Patients Presenting with ACS Treated with PCI: A Propensity Score Analysis from the BleeMACS Registry

    American Journal of Cardiovascular Drugs, Vol. 18, Núm. 4, pp. 299-309

  2. Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score

    International Journal of Cardiology, Vol. 254, pp. 10-15

  3. Gender-related differences in post-discharge bleeding among patients with acute coronary syndrome on dual antiplatelet therapy: A BleeMACS sub-study

    Thrombosis Research, Vol. 168, pp. 156-163

  4. Prediction of Post-Discharge Bleeding in Elderly Patients with Acute Coronary Syndromes: Insights from the BleeMACS Registry

    Thrombosis and Haemostasis, Vol. 118, Núm. 5, pp. 929-938

  5. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy

    European heart journal. Acute cardiovascular care, Vol. 7, Núm. 7, pp. 631-638

  6. Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium

    British Journal of Clinical Pharmacology, Vol. 84, Núm. 2, pp. 280-291

2017

  1. Complete or incomplete coronary revascularisation in patients with myocardial infarction and multivessel disease: A propensity score analysis from the "real-life" BleeMACS (Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome) registry

    EuroIntervention, Vol. 13, Núm. 4, pp. 407-414

  2. Impact of triple antithrombotic therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention in real-world practice

    Journal of Geriatric Cardiology, Vol. 14, Núm. 11, pp. 679-687

  3. Optimal Medical Therapy in Patients with Malignancy Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome: a BleeMACS Sub-Study

    American Journal of Cardiovascular Drugs, Vol. 17, Núm. 1, pp. 61-71

2016

  1. Assessment of effectiveness and security in high pressure postdilatation of bioresorbable vascular scaffolds during percutaneous coronary intervention. Study in a contemporary, non-selected cohort of Spanish patients

    International Journal of Cardiology, Vol. 219, pp. 264-270

  2. Benefício a longo prazo do tratamento com inibidores da enzima de conversão da angiotensina ou antagonistas do recetor da angiotensina, após intervenção coronária percutânea bem-sucedida, no enfarte agudo do miocárdio sem elevação do segmento ST

    Revista Portuguesa de Cardiologia, Vol. 35, Núm. 12, pp. 645-653

  3. BleeMACS: Rationale and design of the study

    Journal of Cardiovascular Medicine, Vol. 17, Núm. 10, pp. 744-749

  4. Change of concept about the regulation of angiotensin II-induced monocyte chemoattractant protein-1 production in human endothelial cells

    Vascular Pharmacology, Vol. 80, pp. 20-34

  5. Comparación entre tres sistemas de puntuación de hemorragia en pacientes con fibrilación auricular no valvular. ¿Qué puede ofrecer la nueva puntuación ORBIT?

    Revista Espanola de Cardiologia, Vol. 69, Núm. 11, pp. 1112-1114

  6. Dominancia coronaria como factor pronóstico: ¿también en infartos anteriores? Respuesta

    Revista Espanola de Cardiologia